BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Grand Pharma Announces Successful Clinical Progress of its Oral 3CL Protease Inhibitor GS221 Against COVID-19

GS221 has conducted 3 clinical trials. Current results of clinical trials show favorable safety and tolerance in the subjects. After administra...

January 02, 2023 | News

Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

The dose-confirming trial will evaluate the safety and effectiveness (immunogenicity) of different formulations of the CIC and influenza vaccine candidates...

January 02, 2023 | News

China to downgrade COVID-19 management to Class B

In a statement released late Monday, the National Health Commission (NHC) renamed the Chinese term for COVID-19 from "novel coronavirus pneumonia" to "nove...

December 28, 2022 | News

China Covid19 Surge : Coronavirus Pandemic Country Profile

What is important to note about these case figures? The reported case figures on a given date do not necessarily show the number of new cases on that da...

December 22, 2022 | News

Pictor announces important COVID-19 trial to map immunity profile of New Zealanders

Pictor, a global leader in immunodiagnostics, today announced an important research project – the Pictor Antibody Clinical Trial (PACT-19) – wh...

December 22, 2022 | News

Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities Clinically valida...

December 15, 2022 | News

Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19

Based on Ascletis' Phase I results of ASC10 and molnupiravir's clinical efficacy data in American, Japanese and Chinese patients, 800 mg twice daily of ASC...

December 13, 2022 | News

China further optimizes COVID-19 response with new measures

Local authorities across China have soon made specific policies to implement the 10 new prevention and control measures recently rolled out by th...

December 12, 2022 | News

Pictor announces funding round after successful launch in New Zealand and US of SARS-CoV-2 Antibody Test

Pictor, a global leader in immunodiagnostics, announced a funding round to help accelerate pipeline product development projects along with mar...

December 05, 2022 | News

YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine

PIKA COVID-19 vaccine is composed of PIKA adjuvant and a stable trimeric form of the recombinant SARS-CoV-2 spike (S) protein as the main antigen component...

November 11, 2022 | News

Merck Highlights New Data for Evobrutinib

Phase II clinical trial data of evobrutinib demonstrated low disease activity and stable EDSS, with NfL levels, a marker of neuronal injury, remaining lo...

October 26, 2022 | News

SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines

CEPI supports up to 40 mil. USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil. could be made available...

October 26, 2022 | News

U.S. FDA Grants EUA for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases,...

October 24, 2022 | News

Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants

Study 307 (Lot Consistency) achieved its primary endpoint, showing that three vaccine lots induced a comparable immune response thereby demonstrating the...

October 13, 2022 | News

Stay Connected